🇺🇸 FDA
Patent

US 11542261

Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors

granted A61KA61K31/496

Quick answer

US patent 11542261 (Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/496